Systemic toxicity is extremely low (Pickart et al., BioMed Res Int 2012)
Only combine peptides that are known to be compatible in solution
Of the 14 semaglutide-treated patients that developed anti-semaglutide antibodies, 7 patients (0.2% of the overall population) developed antibodies cross-reacting with native GLP-1
GHK-Cu stimulates blood vessel formation (angiogenesis), nerve outgrowth, and increases synthesis of collagen, elastin, and glycosaminoglycans
Individual susceptibility varies considerably, with some patients experiencing minimal discomfort while others report more noticeable burning with injections
Chronic treatments with a 5-HT(4) receptor agonist decrease amyloid pathology in the entorhinal cortex and learning and memory deficits in the 5xFAD mouse model of Alzheimers disease